The Effectiveness and Safety of Treating Operable Breast Cancer by the Adjuvant Therapy of Zoledronic Acid and Aromatase Inhibitors and/or Ovarian Function Inhibition
The investigators select patients of primary breast cancer whose hormone receptor is
positive and accepted postoperative adjuvant aromatase inhibitors for endocrine
treatment.Treat them with zoledronic acid 4mg intravenous infusion every six months until
the end of the aromatase treatment. Assess the disease-free survival; overall survival;
combination of security, as well as the situation of bone loss.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
therapeutic assessment
therapeutic assessment
6 months
Yes
Jin Zhang, Professor
Study Chair
TIANJIN CANCER HOSPITAL
United States: Institutional Review Board
jzhang2
NCT01654367
January 2012
December 2013
Name | Location |
---|